Company profile for STADA Arzneimittel

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

STADA is a leading manufacturer of high-quality pharmaceuticals. With a long-standing heritage rooted in pharmacies, we are perceived as a reliable and trustworthy partner for 125 years. With our products we help people protect and regain a dignified and able life. With our proven Generics, we ensure that everyday health remains affordable. To our employees, we offer an attractive working environment in which they can develop ...
STADA is a leading manufacturer of high-quality pharmaceuticals. With a long-standing heritage rooted in pharmacies, we are perceived as a reliable and trustworthy partner for 125 years. With our products we help people protect and regain a dignified and able life. With our proven Generics, we ensure that everyday health remains affordable. To our employees, we offer an attractive working environment in which they can develop personally. STADA focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer healthcare products.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Stadastraße 2-18 61118 Bad Vilbel
Telephone
Telephone
06101 603-0
Linkedin
Linkedin
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

CPhI India 2024

CPhI India 2024

Not Confirmed

envelop Contact Supplier

CPhI India 2024

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
“LGM Pharma has made significant strides in meeting the evolving needs of its clients”
This week, SpeakPharma interviews four senior executives of LGM Pharma — Shailesh Vengurlekar (Senior VP, Quality and Regulatory Affairs), Deepak Thassu (Senior VP, R&D and Regulatory Submission), Selwyn Lustman (Senior VP, Global Sourcing and Procurement), and Mike Stenberg (VP, Business Development). The four VPs talk about expansion in manufacturing capabilities of the Florida-based contract development and manufacturing organization (CDMO), expertise that makes LGM a strong partner and the criteria it adopts while selecting its suppliers.  HIGHLIGHTS// expansion in manufacturing capabilities/ expertise that makes LGM a strong partner/ criteria for selecting its suppliers LGM Pharma recently invested heavily in expanding its CDMO capabilities by 50 percent. Can you share why offering standalone analytical testing services is important to LGM Pharma’s growth strategy? How does it benefit your clients? Vengurlekar: This recent expansion in CDMO capabilities is part of LGM Pharma’s growth strategy that lays importance on diversification. One key area of this diversification is the offering of standalone Analytical Testing Services (ATS). This service plays a crucial role in supporting our clients by providing them with greater flexibility and reliability. LGM Pharma is already a well-established leader in the API supply chain. We have now identified a significant need in the market and are now serving compounding pharmacies, including 503A and 503B facilities. These pharmacies not only require high-quality, GMP-compliant APIs, but also need a trusted, compliant, and capable laboratory to analyze both their APIs and compounded products. Recognizing this opportunity to further support our clients, LGM Pharma has expanded into ATS. We have witnessed tremendous growth since we’ve launched these services. By offering ATS under a separate legal entity — LGM Pharma Solutions — we are able to provide an additional layer of flexibility to our clients. This structure eliminates any conflict of interest. While LGM Pharma LLC handles API supply, LGM Pharma Solutions focuses on delivering top-tier ATS, all under the same LGM Pharma umbrella. This setup enhances trust and allows our clients to work with us more seamlessly. HIGHLIGHTS// diversified into standalone ATS/ well-established leader in API supply chain/ serving compounding pharmacies/ offering APIs and ATS under different legal entities. While suppositories offer clear advantages for certain medications, can you describe how LGM Pharma plans to leverage its expertise in this area to address specific unmet needs in the growing women’s health market? Thassu: We’re taking a dual approach to enhance both our R&D and manufacturing capabilities. First, we’ve introduced a new semi-automatic machine that allows us to produce smaller batches more efficiently. This is particularly important for the suppository segment, where demand doesn’t require large-scale production. The new system enables quicker adjustments to the manufacturing process, providing us with greater flexibility of producing small batches. Second, many of the materials we handle in the women’s health sector are sensitive to heat, light, and oxygen. To address this, we’re upgrading our facility to accommodate these specialized requirements. This ensures we can develop and manufacture products while maintaining the integrity of heat-, light-, and oxygen-sensitive ingredients. Additionally, we’re working closely with clients to prepare for various technical challenges. Whether it’s processing homeopathic ingredients or handling delicate fermentation-based materials, which are highly sensitive to both light and heat, our team has upgraded its skills and equipment to manage these complexities. From technology advancements in manufacturing to specialized handling conditions and improved technical expertise, we’ve made significant strides to ensure we can meet the evolving needs of our clients and their products. HIGHLIGHTS// dual approach to enhance R&D and manufacturing capabilities/ upgrading facilities to accommodate specialized requirements/ working with clients to address challenges. The pandemic underscored supply chain problems. Can you detail the specific criteria LGM Pharma uses while selecting suppliers for its manufacturing processes? Lustman: LGM looks at many facets of a manufacturer before proceeding to approve them for a specific project. We start by checking their regulatory history with the US Food and Drug Administration (FDA) and other authorities. We try to find out if they have received any warning letters. What is their inspection history? Have they received NAIs (no action indicated) and VAIs (voluntary action indicated)? We further investigate the company’s overall business status — we need to know that they are a stable partner to work with in the long term. Manufacturers are then assessed for their overall technology and the number of employees working in various fields, such as R&D, quality control, quality assurance, regulatory affairs, manufacturing, and the educational levels of these employees. Once we have established that the manufacturer is a potential partner, we check their status for a particular project. We look at their advantages, and whether they have a non-infringing route of synthesis (ROS) that will allow early launch. Are they developing a second process that will be more competitive in pricing? And, does the manufacturer have the necessary capacity and/or spare capacity for the project that we are assessing? We need to know whether the drug master file (DMF) has been registered, the current batch size, and the potential for increase in batch size. Pricing is a key indicator — we need to know whether the pricing of the manufacturer is competitive or not, and if the manufacturer will be able to compete in the future as the project matures. LGM always assesses for quality, price, and delivery. Goods must be of the correct quality, at the right price, with delivery time as desired, in order to meet commercial needs. HIGHLIGHTS// investigate various facets of manufacturer before approving them for a project/ look at advantages, non-infringing ROS/ assess for quality, price, delivery Can you highlight specific capabilities and experiences LGM Pharma possesses that make it a strong partner for companies developing antibody-drug-conjugates (ADCs)? Stenberg: ADCs are often peptides linked with small molecules. However, they may also be peptides linked with oligonucleotides. Regardless, LGM can help manage the supply chain associated with the components that are used in the conjugation of the ADC. LGM has extensive experience, and an extensive network around sourcing and managing the supply chain associated with ADC components. LGM’s experience and capabilities extend to sourcing peptides, small molecules or oligonucleotides used in the conjugation process. Additionally, given our deep relationships in the supply chain aspect of this process, LGM may also be able to identify partners who can help with the conjugation process itself. HIGHLIGHTS// extensive experience, network around sourcing, managing supply chain associated with ADC components / identify partners that can help with conjugation process

Impressions: 1116

https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients

#SpeakPharma With LGM Pharma
09 Nov 2024

VLOG #PharmaReel

[Sponsored by another company]

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities
Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 

Impressions: 534

https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

#PharmaFlow by PHARMACOMPASS
21 Nov 2024

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/pharma/germanys-stada-reports-rosy-earnings-first-half-2024-ceo-tempers-sales-rumors

FIERCE PHARMA
28 Aug 2024

https://www.globenewswire.com/news-release/2024/07/22/2916396/0/en/STADA-and-Alvotech-launch-Uzpruvo-the-first-approved-ustekinumab-biosimilar-to-Stelara-across-Europe.html

GLOBENEWSWIRE
22 Jul 2024

https://investors.alvotech.com/news-releases/news-release-details/alvotech-and-stada-add-strategic-alliance-through-denosumab

PRESS RELEASE
12 Jun 2024

https://www.prnewswire.com/news-releases/calliditas-partner-stada-receives-positive-chmp-opinion-recommending-full-approval-for-kinpeygo-for-the-treatment-of-iga-nephropathy-302159841.html

PR NEWSWIRE
31 May 2024

https://endpts.com/iteos-to-raise-120m-xbrane-and-stada-to-out-license-lucentis-biosimilar/

ENDPTS
10 May 2024

https://www.globenewswire.com//news-release/2024/01/10/2806857/0/en/STADA-and-Alvotech-Secure-Approval-for-Uzpruvo-Europe-s-First-Ustekinumab-Biosimilar-to-Stelara.html

GLOBENEWSWIRE
10 Jan 2024

Drugs in Development

read-more
read-more

Details:

Kinpeygo (budesonide)is a modified-release capsule, glucocorticoid receptor agonist, which is indicated for the treatment of patients with primary IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Brand Name: Kinpeygo

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 26, 2024

blank

01

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Kinpeygo (budesonide)is a modified-release capsule, glucocorticoid receptor agonist, which is indicated for the treatment of patients with primary IgA nephropathy.

Brand Name : Kinpeygo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 26, 2024

blank

Details:

Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.


Lead Product(s): Ustekinumab

Therapeutic Area: Gastroenterology Brand Name: Uzpruvo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Alvotech

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 22, 2024

blank

02

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.

Brand Name : Uzpruvo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

July 22, 2024

blank

Details:

The partnership aims to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively.


Lead Product(s): Denosumab

Therapeutic Area: Musculoskeletal Brand Name: AVT03

Study Phase: Phase IIIProduct Type: Large molecule

Recipient: Alvotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 11, 2024

blank

03

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : The partnership aims to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively.

Brand Name : AVT03

Molecule Type : Large molecule

Upfront Cash : Undisclosed

June 11, 2024

blank

Details:

Under the agreement, Bio-Thera Solutions will maintain responsibility for development, manufacturing, and supply of BAT2506, a biosimilar candidate to Simponi® (golimumab).


Lead Product(s): Gollmumab

Therapeutic Area: Immunology Brand Name: BAT2506

Study Phase: Phase IIIProduct Type: Large molecule

Recipient: Bio-Thera Solutions

Deal Size: $157.5 million Upfront Cash: $10.0 million

Deal Type: Licensing Agreement May 28, 2024

blank

04

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Under the agreement, Bio-Thera Solutions will maintain responsibility for development, manufacturing, and supply of BAT2506, a biosimilar candidate to Simponi® (golimumab).

Brand Name : BAT2506

Molecule Type : Large molecule

Upfront Cash : $10.0 million

May 28, 2024

blank

Details:

Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.


Lead Product(s): Ustekinumab

Therapeutic Area: Gastroenterology Brand Name: Uzpruvo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Alvotech

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2024

blank

05

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.

Brand Name : Uzpruvo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 10, 2024

blank

Details:

Uzpruvo (ustekinumab) biosimilar candidate to Stelara is a human IgG1κ monoclonal antibody (mAb), which is investigated for the treatment of moderate to severe chronic plaque-type psoriasis.


Lead Product(s): Ustekinumab

Therapeutic Area: Dermatology Brand Name: Uzpruvo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 10, 2023

blank

06

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Uzpruvo (ustekinumab) biosimilar candidate to Stelara is a human IgG1κ monoclonal antibody (mAb), which is investigated for the treatment of moderate to severe chronic plaque-type psoriasis.

Brand Name : Uzpruvo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

November 10, 2023

blank

Details:

Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.


Lead Product(s): Ranibizumab

Therapeutic Area: Ophthalmology Brand Name: Ximluci

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Xbrane Biopharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2023

blank

07

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation...

Brand Name : Ximluci

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 16, 2023

blank

Details:

Hukyndra (adalimumab) is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor. Adalimumab is first product launched through an exclusive strategic partnership announced by Alvotech and STADA in November 2019.


Lead Product(s): Adalimumab

Therapeutic Area: Dermatology Brand Name: Hukyndra

Study Phase: ApprovedProduct Type: Large molecule

Recipient: Alvotech

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 07, 2022

blank

08

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Hukyndra (adalimumab) is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor. Adalimumab is first product launched through an exclusive strategic partnership announced by Alvotech and STADA in November 2019...

Brand Name : Hukyndra

Molecule Type : Large molecule

Upfront Cash : Not Applicable

December 07, 2022

blank

Details:

Hukyndra (adalimumab), Hukyndra is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor, increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Brand Name: Hukyndra

Study Phase: ApprovedProduct Type: Large molecule

Recipient: Alvotech

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 22, 2022

blank

09

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Hukyndra (adalimumab), Hukyndra is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor, increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab.

Brand Name : Hukyndra

Molecule Type : Large molecule

Upfront Cash : Not Applicable

September 22, 2022

blank

Details:

Nefecon (budesonide) is a patented novel, investigational oral formulation of a potent and well-known active substance – budesonide – for targeted release. The formulation is designed to deliver the drug to the ileum where the Peyer’s patches are concentrated.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Brand Name: Nefecon

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Calliditas Therapeutics AB

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 20, 2022

blank

10

Pharma Manufacturing 2024
Not Confirmed
Pharma Manufacturing 2024
Not Confirmed

Details : Nefecon (budesonide) is a patented novel, investigational oral formulation of a potent and well-known active substance – budesonide – for targeted release. The formulation is designed to deliver the drug to the ileum where the Peyer’s patches are c...

Brand Name : Nefecon

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 20, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Brand Name : ACECLOFENAC EG

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : ACECLOFENAC EG

arrow
euroPLX 86 Munich
Not Confirmed

EG Spa

Dosage Form : Film-Coated Tablets

Brand Name : ACECLOFENAC EG

Dosage Strength : 100 mg

Packaging : 40 UNITS 100 MG - ORAL USE

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

02

Brand Name : Aceclofenac Stada 10...

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : Aceclofenac Stada 10...

arrow
euroPLX 86 Munich
Not Confirmed

STADA Arzneimittel

Dosage Form : Tablet

Brand Name : Aceclofenac Stada 100Mg 2...

Dosage Strength : 100 Mg/Tablet

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

03

Brand Name : Aceclofenac Stada 10...

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : Aceclofenac Stada 10...

arrow
euroPLX 86 Munich
Not Confirmed

STADA Arzneimittel

Dosage Form : Tablet

Brand Name : Aceclofenac Stada 100Mg 4...

Dosage Strength : 100 Mg/Tablet

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

04

Brand Name : Aceclofenac Stada Ge...

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : Aceclofenac Stada Ge...

arrow
euroPLX 86 Munich
Not Confirmed

STADA Arzneimittel

Dosage Form : Tablet

Brand Name : Aceclofenac Stada Generic...

Dosage Strength : 100 Mg/Tablet

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

05

Brand Name : Aceclofenac Stada Ge...

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : Aceclofenac Stada Ge...

arrow
euroPLX 86 Munich
Not Confirmed

STADA Arzneimittel

Dosage Form : Tablet

Brand Name : Aceclofenac Stada Generic...

Dosage Strength : 100 Mg/Tablet

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

06

Brand Name : Tianzakt

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : Tianzakt

arrow
euroPLX 86 Munich
Not Confirmed

STADA Arzneimittel

Dosage Form : GASTRO

Brand Name : Tianzakt

Dosage Strength : 100 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

07

Brand Name : ACETYLSALICYLIC ACID...

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : ACETYLSALICYLIC ACID...

arrow
euroPLX 86 Munich
Not Confirmed

EG Spa

Dosage Form : Gastro-Resistant Tablets

Brand Name : ACETYLSALICYLIC ACID EG

Dosage Strength : 100 mg

Packaging : 30 UNITS 100 MG - ORAL USE

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

08

Brand Name : acyclovir Tablets

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : acyclovir Tablets

arrow
euroPLX 86 Munich
Not Confirmed

STADA Arzneimittel

Dosage Form : TABLET

Brand Name : acyclovir Tablets

Dosage Strength : 800 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

09

Brand Name : acyclovir Tablets

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : acyclovir Tablets

arrow
euroPLX 86 Munich
Not Confirmed

STADA Arzneimittel

Dosage Form : TABLET

Brand Name : acyclovir Tablets

Dosage Strength : 200 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

10

Brand Name : acyclovir Tablets

euroPLX 86 Munich
Not Confirmed
arrow

Brand Name : acyclovir Tablets

arrow
euroPLX 86 Munich
Not Confirmed

STADA Arzneimittel

Dosage Form : TABLET

Brand Name : acyclovir Tablets

Dosage Strength : 400 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Brand Name : Aceclofenac Stada Ge...

American Pharma Summit
Not Confirmed
arrow

Brand Name : Aceclofenac Stada Ge...

arrow
American Pharma Summit
Not Confirmed

STADA Arzneimittel

Dosage Form : Tablet

Dosage Strength : 100 Mg/Tablet

Packaging :

Brand Name : Aceclofenac Stada Generic 100...

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

02

Brand Name : Aceclofenac Stada 10...

American Pharma Summit
Not Confirmed
arrow

Brand Name : Aceclofenac Stada 10...

arrow
American Pharma Summit
Not Confirmed

STADA Arzneimittel

Dosage Form : Tablet

Dosage Strength : 100 Mg/Tablet

Packaging :

Brand Name : Aceclofenac Stada 100Mg 20 Co...

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

03

Brand Name : Aceclofenac Stada Ge...

American Pharma Summit
Not Confirmed
arrow

Brand Name : Aceclofenac Stada Ge...

arrow
American Pharma Summit
Not Confirmed

STADA Arzneimittel

Dosage Form : Tablet

Dosage Strength : 100 Mg/Tablet

Packaging :

Brand Name : Aceclofenac Stada Generic 100...

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

04

Brand Name : Aceclofenac Stada 10...

American Pharma Summit
Not Confirmed
arrow

Brand Name : Aceclofenac Stada 10...

arrow
American Pharma Summit
Not Confirmed

STADA Arzneimittel

Dosage Form : Tablet

Dosage Strength : 100 Mg/Tablet

Packaging :

Brand Name : Aceclofenac Stada 100Mg 40 Co...

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

05

Brand Name : ACECLOFENAC EG

American Pharma Summit
Not Confirmed
arrow

Brand Name : ACECLOFENAC EG

arrow
American Pharma Summit
Not Confirmed

EG Spa

Dosage Form : Film-Coated Tablets

Dosage Strength : 100 mg

Packaging : 40 UNITS 100 MG - ...

Brand Name : ACECLOFENAC EG

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

06

Brand Name : Tianzakt

American Pharma Summit
Not Confirmed
arrow

Brand Name : Tianzakt

arrow
American Pharma Summit
Not Confirmed

STADA Arzneimittel

Dosage Form : GASTRO

Dosage Strength : 100 MG

Packaging :

Brand Name : Tianzakt

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

07

Brand Name : ACETYLSALICYLIC ACID...

American Pharma Summit
Not Confirmed
arrow

Brand Name : ACETYLSALICYLIC ACID...

arrow
American Pharma Summit
Not Confirmed

EG Spa

Dosage Form : Gastro-Resistant Tablets

Dosage Strength : 100 mg

Packaging : 30 UNITS 100 MG - ...

Brand Name : ACETYLSALICYLIC ACID EG

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

08

Brand Name : acyclovir Tablets

American Pharma Summit
Not Confirmed
arrow

Brand Name : acyclovir Tablets

arrow
American Pharma Summit
Not Confirmed

STADA Arzneimittel

Dosage Form : TABLET

Dosage Strength : 800 MG

Packaging :

Brand Name : acyclovir Tablets

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

09

Brand Name : acyclovir Tablets

American Pharma Summit
Not Confirmed
arrow

Brand Name : acyclovir Tablets

arrow
American Pharma Summit
Not Confirmed

STADA Arzneimittel

Dosage Form : TABLET

Dosage Strength : 400 MG

Packaging :

Brand Name : acyclovir Tablets

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

10

Brand Name : acyclovir Tablets

American Pharma Summit
Not Confirmed
arrow

Brand Name : acyclovir Tablets

arrow
American Pharma Summit
Not Confirmed

STADA Arzneimittel

Dosage Form : TABLET

Dosage Strength : 200 MG

Packaging :

Brand Name : acyclovir Tablets

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty